Beth Israel Deaconess Medical Center neurosurgeons offer deep brain stimulation, a brain stimulator device, to treat movement disorders. Learn more.

There is still no cure for Parkinson’s disease, but the U.S. Food and Drug Administration (FDA) approved a new deep brain stimulator that could benefit patients with the motor condition. On Feb 24, ...

Medicare covers deep brain stimulation (DBS) for eligible people diagnosed with essential tremors or idiopathic Parkinson’s disease to help reduce tremors and improve daily activities. To qualify for ...

Deep brain stimulation can significantly reduce depressive symptoms in some individuals. Knowing what to expect before and after the procedure may help you determine if it’s right for you. Deep brain ...

In a new frontier for deep brain stimulation, researchers used A.I. to develop individualized algorithms, which helped a skateboarder and other patients with Parkinson’s disease. By Pam Belluck ...

Deep brain stimulation is a surgical brain therapy used to treat symptoms of movement disorders such as dystonia, Parkinson’s disease and epilepsy. Performing over 100 DBS procedures annually, the ...

While stuttering was believed to have purely psychological causes up until about 30 years ago, scientists today attribute it to a variety of factors capable of contributing to its development. For ...

Electricity is the brain’s language. For a decade, National Institutes of Health (NIH) funding and philanthropy have enabled UC San Francisco physician-scientists to decipher this language and use ...

An ultrasound device that can precisely stimulate areas deep in the brain without surgery has been developed by researchers from UCL and the University of Oxford, opening up new possibilities for ...

For the first time, researchers at the Netherlands Institute for Neuroscience and Amsterdam UMC have identified what happens in neural networks deep within the brain during obsessive thoughts and ...

Deep brain stimulation—implants in the brain that act as a kind of "pacemaker"—has led to clinical improvements in half of the participants with treatment-resistant severe depression in an open-label ...